Patent 7772255 was granted and assigned to Supratek Pharma Inc. on August, 2010 by the United States Patent and Trademark Office.
The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.